Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC “Barrs” Firm From Anticompetitive Agreements

This article was originally published in The Pink Sheet Daily

Executive Summary

Federal Trade Commission gets rare victory in settlement with Barr over charges that cash payment delayed entry of generic Ovcon.

You may also be interested in...

Pharmas Should Be Less Aggressive With Reverse Payments, Former FTC Counsel Advises

Payments to delay generic entry could be banned under pending legislation before Congress.

FTC Enjoins Warner Chilcott From Providing “Anything Of Value” To ANDA Filers

Commission settles charges against the brand drug maker related to generic Ovcon 35.

Supreme Court Denies Certiorari To FTC v. Schering-Plough

The high court denies the Federal Trade Commission’s petition to hear the case regarding issues raised by brand companies’ reverse payments to generic firms.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts